vs
CSG SYSTEMS INTERNATIONAL INC（CSGS）とPacira BioSciences, Inc.（PCRX）の財務データ比較。上の社名をクリックして会社を切り替えられます
CSG SYSTEMS INTERNATIONAL INCの直近四半期売上が大きい（$323.1M vs $177.4M、Pacira BioSciences, Inc.の約1.8倍）。CSG SYSTEMS INTERNATIONAL INCの純利益率が高く（2.2% vs 1.6%、差は0.5%）。Pacira BioSciences, Inc.の前年同期比売上増加率が高い（5.0% vs 2.0%）。過去8四半期でCSG SYSTEMS INTERNATIONAL INCの売上複合成長率が高い（4.6% vs -0.2%）
中国南玻集団股フン有限公司は中国最大級の建築用ガラスメーカーで、浮きガラス、建築用ガラス、ディスプレイ用ガラス、自動車用ガラス、コーティングガラス、鏡、カラーフィルターガラス、太陽光発電用ガラス、省エネガラスなど多種多様なガラス製品の製造・販売を手がけています。
Pacira BioSciences社は非オピオイド系疼痛管理ソリューションの開発・商業化に特化した専門製薬企業で、主に米国の病院や外来手術センターなどの医療機関に術後鎮痛向け製品を提供し、一部海外市場への展開も進めています。
CSGS vs PCRX — 直接比較
損益計算書 — Q4 FY2025 vs Q1 FY2026
| 指標 | | |
|---|---|---|
| 売上 | $323.1M | $177.4M |
| 純利益 | $7.0M | $2.9M |
| 粗利率 | 50.0% | — |
| 営業利益率 | 9.0% | 3.9% |
| 純利益率 | 2.2% | 1.6% |
| 売上前年比 | 2.0% | 5.0% |
| 純利益前年比 | -79.7% | — |
| EPS（希薄化後） | $0.24 | $0.07 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q1 26 | — | $177.4M | ||
| Q4 25 | $323.1M | $196.9M | ||
| Q3 25 | $303.6M | $179.5M | ||
| Q2 25 | $297.1M | $181.1M | ||
| Q1 25 | $299.5M | $168.9M | ||
| Q4 24 | $316.7M | $187.3M | ||
| Q3 24 | $295.1M | $168.6M | ||
| Q2 24 | $290.3M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | $7.0M | — | ||
| Q3 25 | $20.5M | $5.4M | ||
| Q2 25 | $12.3M | $-4.8M | ||
| Q1 25 | $16.1M | $4.8M | ||
| Q4 24 | $34.5M | — | ||
| Q3 24 | $19.1M | $-143.5M | ||
| Q2 24 | $13.8M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | 50.0% | 79.5% | ||
| Q3 25 | 48.1% | 80.9% | ||
| Q2 25 | 49.5% | 77.4% | ||
| Q1 25 | 48.4% | 79.7% | ||
| Q4 24 | 51.3% | 78.7% | ||
| Q3 24 | 49.4% | 76.9% | ||
| Q2 24 | 47.3% | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | 9.0% | 1.2% | ||
| Q3 25 | 10.0% | 3.5% | ||
| Q2 25 | 10.0% | 4.7% | ||
| Q1 25 | 9.8% | 1.2% | ||
| Q4 24 | 13.4% | 13.2% | ||
| Q3 24 | 10.8% | -82.8% | ||
| Q2 24 | 8.8% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | 2.2% | — | ||
| Q3 25 | 6.7% | 3.0% | ||
| Q2 25 | 4.1% | -2.7% | ||
| Q1 25 | 5.4% | 2.8% | ||
| Q4 24 | 10.9% | — | ||
| Q3 24 | 6.5% | -85.1% | ||
| Q2 24 | 4.8% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | $0.24 | $0.05 | ||
| Q3 25 | $0.73 | $0.12 | ||
| Q2 25 | $0.44 | $-0.11 | ||
| Q1 25 | $0.57 | $0.10 | ||
| Q4 24 | $1.20 | $0.38 | ||
| Q3 24 | $0.67 | $-3.11 | ||
| Q2 24 | $0.48 | $0.39 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $180.0M | $144.3M |
| 総負債低いほど良い | $539.5M | — |
| 株主資本純資産 | $283.7M | $653.9M |
| 総資産 | $1.5B | $1.2B |
| 負債/資本比率低いほどレバレッジが低い | 1.90× | — |
8四半期トレンド — 暦四半期で整列
| Q1 26 | — | $144.3M | ||
| Q4 25 | $180.0M | $238.4M | ||
| Q3 25 | $158.4M | $246.3M | ||
| Q2 25 | $145.9M | $445.9M | ||
| Q1 25 | $136.0M | $493.6M | ||
| Q4 24 | $161.8M | $484.6M | ||
| Q3 24 | $118.4M | $453.8M | ||
| Q2 24 | $110.4M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | $539.5M | $372.2M | ||
| Q3 25 | $538.6M | $376.7M | ||
| Q2 25 | $537.8M | $580.5M | ||
| Q1 25 | $537.6M | $583.4M | ||
| Q4 24 | $538.5M | $585.3M | ||
| Q3 24 | $539.5M | — | ||
| Q2 24 | $540.5M | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | $283.7M | $693.1M | ||
| Q3 25 | $289.5M | $727.2M | ||
| Q2 25 | $290.7M | $757.8M | ||
| Q1 25 | $283.1M | $798.5M | ||
| Q4 24 | $282.6M | $778.3M | ||
| Q3 24 | $288.4M | $749.6M | ||
| Q2 24 | $273.3M | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $1.5B | $1.3B | ||
| Q3 25 | $1.5B | $1.3B | ||
| Q2 25 | $1.4B | $1.5B | ||
| Q1 25 | $1.4B | $1.6B | ||
| Q4 24 | $1.5B | $1.6B | ||
| Q3 24 | $1.4B | $1.5B | ||
| Q2 24 | $1.4B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | 1.90× | 0.54× | ||
| Q3 25 | 1.86× | 0.52× | ||
| Q2 25 | 1.85× | 0.77× | ||
| Q1 25 | 1.90× | 0.73× | ||
| Q4 24 | 1.91× | 0.75× | ||
| Q3 24 | 1.87× | — | ||
| Q2 24 | 1.98× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $59.2M | — |
| フリーキャッシュフロー営業CF - 設備投資 | $55.8M | — |
| FCFマージンFCF / 売上 | 17.3% | — |
| 設備投資強度設備投資 / 売上 | 1.1% | — |
| キャッシュ転換率営業CF / 純利益 | 8.46× | — |
| 直近12ヶ月FCF直近4四半期 | $141.4M | — |
8四半期トレンド — 暦四半期で整列
| Q1 26 | — | — | ||
| Q4 25 | $59.2M | $43.7M | ||
| Q3 25 | $47.9M | $60.8M | ||
| Q2 25 | $37.3M | $12.0M | ||
| Q1 25 | $11.5M | $35.5M | ||
| Q4 24 | $82.5M | $33.1M | ||
| Q3 24 | $39.5M | $53.9M | ||
| Q2 24 | $43.1M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | $55.8M | $43.5M | ||
| Q3 25 | $43.9M | $57.0M | ||
| Q2 25 | $34.6M | $9.3M | ||
| Q1 25 | $7.1M | $26.9M | ||
| Q4 24 | $76.6M | $31.0M | ||
| Q3 24 | $32.0M | $49.8M | ||
| Q2 24 | $38.8M | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | 17.3% | 22.1% | ||
| Q3 25 | 14.5% | 31.7% | ||
| Q2 25 | 11.6% | 5.1% | ||
| Q1 25 | 2.4% | 15.9% | ||
| Q4 24 | 24.2% | 16.6% | ||
| Q3 24 | 10.8% | 29.6% | ||
| Q2 24 | 13.4% | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | 1.1% | 0.1% | ||
| Q3 25 | 1.3% | 2.2% | ||
| Q2 25 | 0.9% | 1.5% | ||
| Q1 25 | 1.5% | 5.1% | ||
| Q4 24 | 1.9% | 1.1% | ||
| Q3 24 | 2.5% | 2.4% | ||
| Q2 24 | 1.5% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | 8.46× | — | ||
| Q3 25 | 2.34× | 11.20× | ||
| Q2 25 | 3.04× | — | ||
| Q1 25 | 0.71× | 7.37× | ||
| Q4 24 | 2.39× | — | ||
| Q3 24 | 2.07× | — | ||
| Q2 24 | 3.12× | 2.82× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
CSGS
| Software As A Service And Related Solutions | $287.2M | 89% |
| License And Service | $22.6M | 7% |
| Maintenance | $13.3M | 4% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
